[HTML][HTML] Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer
Y Ling, X Yang, W Li, Z Li, L Yang, T Qiu, L Guo… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) is a novel target for therapy in a
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
[引用][C] Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer
Y Ling, X Yang, W Li, Z Li, L Yang, T Qiu, L Guo… - Oncotarget, 2016 - cir.nii.ac.jp
Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI
therapy in non-small cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報 …
therapy in non-small cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報 …
[PDF][PDF] Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer
Y Ling, X Yang, W Li, Z Li, L Yang, T Qiu, L Guo… - researchgate.net
Background: Epidermal growth factor receptor (EGFR) is a novel target for therapy in a
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
[PDF][PDF] Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer
Y Ling, X Yang, W Li, Z Li, L Yang, T Qiu, L Guo… - pdfs.semanticscholar.org
Background: Epidermal growth factor receptor (EGFR) is a novel target for therapy in a
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer
Y Ling, X Yang, W Li, Z Li, L Yang, T Qiu… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) is a novel target for therapy in a
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.
Y Ling, X Yang, W Li, Z Li, L Yang, T Qiu, L Guo… - Oncotarget, 2016 - europepmc.org
Background Epidermal growth factor receptor (EGFR) is a novel target for therapy in a
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good …
[HTML][HTML] Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer
Y Ling, X Yang, W Li, Z Li, L Yang, T Qiu, L Guo… - Oncotarget, 2016 - oncotarget.com
Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI
therapy in non-small cell lung cancer | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget …
therapy in non-small cell lung cancer | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget …
Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer
Y Ling, X Yang, W Li, Z Li, L Yang, T Qiu, L Guo… - Oncotarget, 2016 - oncotarget.com
Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI
therapy in non-small cell lung cancer | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget …
therapy in non-small cell lung cancer | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget …